Abbott Laboratories (ABT)
Boston Scientific Bets on Growth Through Strategic M&A Deals
BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Abbott: Three Supercycles, Mispriced At A 10-Year Low
Abbott Laboratories trades at a decade low of 17.7x forward earnings despite 13.2% Q1 2026 Medical Devices growth and a 54-year dividend streak. Three underappreciated catalysts—Exact Sciences synergy, CMS CGM expansion, and Nutrition margin recovery—could drive $1.27–$1.73 incremental EPS by 2028–2029. Consensus underestimates ABT's commercial leverage, with distribution synergies and CMS reimbursement expansion offering asymmetric upside not priced into current models.
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook
ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott Laboratories $ABT Shares Purchased by Advisors Capital Management LLC
Advisors Capital Management LLC increased its holdings in shares of Abbott Laboratories (NYSE: ABT) by 3.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 209,652 shares of the healthcare product maker's stock after purchasing an additional 6,743 shares during the quarter.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Abbott Laboratories: Buying A Healthcare Giant On Sale
After reaching a cycle high of $141.23 per share in early March 2025, Abbott Laboratories closed at $92.48 as of April 23rd, the equivalent of a ~35% decline in just over a year. This is now one of the most severe drawdowns in the company's history, even exceeding in severity the price declines experienced during the 2008-09 global financial crisis. Along with the release of the Q1-26 earnings last week, management has guided for adjusted diluted EPS between $5.38 and $5.58 per share in fiscal 2026.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
